Hansoh Pharma's Ris-Rez cuts progression or death risk by 67% in Phase 3 osteosarcoma trial

PUBT · 1d ago
Hansoh Pharma's Ris-Rez cuts progression or death risk by 67% in Phase 3 osteosarcoma trial
  • Hansoh Pharma announced Oct. 27, 2026, that risvutatug rezetecan met the Phase 3 ARTEMIS-011 trial's primary progression-free survival endpoint.
  • The drug reduced disease progression or death risk by 67% versus gemcitabine and docetaxel, a statistically significant benefit.
  • Patients had relapsed or refractory osteosarcoma following at least two prior treatment lines; dosing was 12.0 mg/kg every three weeks.
  • China's drug regulator accepted the osteosarcoma biologics license application on Sept. 24, 2026, granting priority review.
  • GSK holds exclusive development and commercialization rights outside mainland China, Hong Kong, Macau and Taiwan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.